Oncology Intelligence Digest July 24, 2026 The FDA approved GSK’s Jideytro (zidesamtinib) for ROS1-positive NSCLC on July 24,…
Oncology Intelligence Membership Required
You must be a Oncology Intelligence member to access this content.
Already a member? Log in here